Key result
The Omicron variant showed the greatest escape from neutralization by post-vaccination sera with a 38-fold reduction compared to the progenitor virus, though booster sera reduced this to a 19-fold reduction.
Why the study?
Emerging SARS-CoV-2 variant lineages exacerbated the COVID-19 pandemic, requiring assessment and ranking of the risk of variants of concern and interest based on their ability to escape vaccine-induced antibodies.
COVID-19 mRNA vaccine booster doses elicit moderate neutralizing activity against the highly evasive Omicron variant, supporting the use of booster vaccination.
Answers are grounded in this paper and cite their sources.
Antibody escape data may guide variant surveillance; leaves open real-world impact on vaccine effectiveness.
Introductory The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence of many new variant lineages that have exacerbated the COVID-19 pandemic. Some of those variants were designated as variants of concern/interest (VOC/VOI) by national or international authorities based on many factors including their potential impact on vaccines. To ascertain and rank the risk of VOCs and VOIs, we analyzed their ability to escape from vaccine-induced antibodies. The variants showed differential reductions in neutralization and replication titers by post-vaccination sera. Although the Omicron variant showed the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retained moderate neutralizing activity against that variant. Therefore, vaccination remains the most effective strategy to combat the COVID-19 pandemic.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) studied SARS-CoV-2. SARS-CoV-2 variants (Omicron) vs. Progenitor 614D reference virus was evaluated on Neutralization titer (FRNT50) fold reduction (38-fold reduction). The Omicron variant showed the greatest escape from neutralization by post-vaccination sera with a 38-fold reduction compared to the progenitor virus, though booster sera reduced this to a 19-fold reduction.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: